T细胞淋巴母细胞淋巴瘤与白血病:源自共同癌前祖细胞的不同疾病?
本文综述T细胞淋巴母细胞淋巴瘤(T-LBL)与T细胞急性淋巴细胞白血病(T-ALL)的临床、免疫表型及分子遗传学差异,探讨二者是同一疾病的不同表现还是源自共同恶性前体细胞但各具特定致病需求的不同疾病,并指出深入理解T-LBL有助于将已证实的T-ALL疗法应用于T-LBL患者。
要点
- T-LBL与T-ALL均起源于未成熟前体T细胞转化,二者关系存在同一疾病与不同疾病两种观点。
- T-ALL的遗传学特征已被深入研究,而T-LBL的驱动突变所知甚少。
- T-LBL与T-ALL可能源自共同恶性前体细胞,但各自具有不同的致病需求或细胞依赖性。
核心结论
- T-LBL与T-ALL可能同时源自共同恶性前体细胞,但各自具有特定的致病需求或细胞依赖性,这些需求在淋巴组织内基质包埋的原始细胞与孤立的白血病细胞之间存在差异。
研究设计与样本
- 本文为综述,汇总T-LBL与T-ALL在临床表现、遗传易感性及附加突变获得方面的近期研究结果。
主要发现
- 来自独立T-LBL与T-ALL研究的临床、免疫表型及分子观察结果的比较,支持T-LBL与T-ALL为同一疾病不同表现的理论。
临床怎么用
- 作者认为,更深入地理解T-LBL与T-ALL的关系可能有助于将已证实的T-ALL疗法应用于T-LBL患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell lymphoblastic lymphoma (T-LBL) and lymphoblastic leukemia (T-ALL) represent malignancies that arise from the transformation of immature precursor T cells. Similarities in T-LBL and T-ALL have raised the question whether these entities represent 1 disease or reflect 2 different diseases. The genetic profiles of T-ALL have been thoroughly investigated over the last 2 decades, whereas fairly little is known about genetic driver mutations in T-LBL. Nevertheless, the comparison of clinical, immunophenotypic, and molecular observations from independent T-LBL and T-ALL studies lent strength to the theory that T-LBL and T-ALL reflect different presentations of the same disease. Alternatively, T-LBL and T-ALL may simultaneously evolve from a common malignant precursor cell, each having their own specific pathogenic requirements or cellular dependencies that differ among stroma-embedded blasts in lymphoid tissues compared with solitary leukemia cells. This review aims to cluster recent findings with regard to clinical presentation, genetic predisposition, and the acquisition of additional mutations that may give rise to differences in gene expression signatures among T-LBL and T-ALL patients. Improved insight in T-LBL in relation to T-ALL may further help to apply confirmed T-ALL therapies to T-LBL patients.
引用
- Kroeze E, Loeffen JLC, Poort VM, et al. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? Blood Adv. 2020. PMID: 32722786. doi:10.1182/bloodadvances.2020001822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。